014950.Kq

The company's capital structure is characterized by a low debt-to-equity ratio of 0.04, indicating a conservative leverage position relative to its equity base. However, the company's liquidity position is assessed as medium, with a current ratio of 4.85, suggesting it has sufficient short-term assets to cover its liabilities, but with some room for improvement in cash flow management. Free cash flow is negative at -3,096,705,570 KRW, which is a concern given the company's operating cash flow of 2,076,543,430 KRW, indicating that capital expenditures are outpacing operating cash inflows.

Profitability metrics show a return on equity of -1.09% and a return on assets of -0.89%, both of which are negative and significantly below the industry median for pharmaceutical firms. This suggests the company is underperforming in terms of generating returns for shareholders and utilizing its assets efficiently. Gross profit of 42,359,589,780 KRW is strong, but the net loss of 754,888,320 KRW indicates that operating expenses and other costs are eroding profitability.

The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases exposure to market-specific risks, particularly in the pharmaceutical industry where regulatory and pricing pressures can vary significantly by region.

The company's growth trajectory is uncertain, with no clear indication of revenue growth in the current fiscal year. Capital expenditures of -3,431,506,020 KRW suggest a significant investment in infrastructure or R&D, but the negative free cash flow indicates that these investments are not yet generating positive returns. The outlook for the next fiscal year remains unclear, with no specific guidance provided in the available data.

Risk factors include a net cash position that is negative after subtracting total debt, which could limit the company's ability to fund operations or invest in growth opportunities without external financing. The risk of dilution is assessed as low, with no significant changes in shares outstanding between basic and diluted shares. However, the company's negative net income and high capital expenditures may necessitate future equity or debt financing, which could introduce dilution risk.

Recent events include the filing of financial statements that reveal the company's current financial position, including the net loss and negative free cash flow. No recent earnings call transcripts or press releases were available to provide additional context on the company's strategic direction or operational performance.